Chlorozotocin treatment of advanced gastrointestinal cancer

✍ Scribed by Veronesi, A. ;Magri, M. D. ;Tirelli, U. ;Galligioni, E. ;Figoli, F. ;Zagonel, V. ;Tumolo, S. ;Grigoletto, E.

• Publisher: John Wiley and Sons
• Year: 1983
• Tongue: English
• Weight: 215 KB
• Volume: 11
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/mpo.2950110515

✦ Synopsis

Abstract

From April 1981 to December 1981, 34 consecutive patients with advanced gastrointestinal cancer were treated with chlorozotocin at the dosage of 40 mg/m~2~ daily for 5 consecutive days (30 mg/m~2~ in patients pretreated with chemotherapy) every 6 weeks. In the 30 patients evaluable for response, a 3.3% objective response rate was encountered. Toxicity was not significant and consisted mainly in reversible myelosuppression. Median survival was 3 months. At the dosage and schedule used, chlorozotocin does not seem to be an effective agent in the treatment of advanced gastrointestinal cancer.